Karl Baum

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Incidental white-matter foci on MRI in "healthy" subjects: evidence of subtle cognitive dysfunction

Karl Baum, Carsten Schulte, W. Girke et al. · Neuroradiology · 1996 · 67 citations

Medicine, White Matter, Neuroimaging +9

Mixed connective tissue disease: recurrent episodes of optic neuropathy and transverse myelopathy. Successful treatment with plasmapheresis

K.-M. Flechtner, Karl Baum · Journal of the Neurological Sciences · 1994 · 35 citations

Transverse Myelopathy, Peripheral Nerves, Ophthalmology +7

Systemic lupus erythematosus: neuropsychiatric signs and symptoms related to cerebral MRI findings

Karl Baum, U. Hopf, C. Nehrig et al. · Clinical Neurology and Neurosurgery · 1993 · 33 citations

Neuropsychology, Systemic Lupus Erythematosus, Lupus +11

Hepatitis E masquerading as drug-induced liver injury

Emerson Y. Chen, Karl Baum, William Collins et al. · Hepatology · 2012 · 28 citations · Full text